This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209), Journal of Clinical Oncology, September 2020, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.20.01076.
You can read the full text:
Carboplatin plus paclitaxel (TC) should be the global first-line standard treatment for advanced endometrial cancer, new findings suggest. The combination proved to be noninferior to paclitaxel-doxorubicin-cisplatin (TAP) in terms of response, progression-free survival, and overall survival, and with lower toxicity. Overall survival was a median of 37 months for TC and 41 months for TAP, and there were more adverse events of grade 3 or higher with TAP. The data were initially presented at the 2012 annual meeting of the Society of Gynecologic Oncology. In the original presentation, lead author David Scott Miller, MD, said this combination should be the standard of care in this setting. Miller is professor of obstetrics and gynecology at the University of Texas Southwestern Medical Center, Dallas, Texas. "This subsequent long-term follow-up publication confirmed that," he told Medscape Medical News. "TAP is now rarely used."
Carboplatin plus paclitaxel (TC) should be the global first-line standard treatment for advanced endometrial cancer, new findings suggest. The combination proved to be noninferior to paclitaxel-doxorubicin-cisplatin (TAP) in terms of response, progression-free survival, and overall survival, and with lower toxicity. Overall survival was a median of 37 months for TC and 41 months for TAP, and there were more adverse events of grade 3 or higher with TAP. The data were initially presented at the 2012 annual meeting of the Society of Gynecologic Oncology. In the original presentation, lead author David Scott Miller, MD, said this combination should be the standard of care in this setting. Dr. Miller is professor of obstetrics and gynecology at the University of Texas Southwestern Medical Center, Dallas.
The paper “Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase 3 Trial (NRG Oncology/GOG 0209)” to be published in the Journal of Clinical Oncology has been chosen as that issue’s “Editor’s Choice” based on the study’s findings that carboplatin and paclitaxel should be considered the first-line therapy for advanced or recurrent endometrial cancer. This randomized phase III trial compared how well two different combination chemotherapy regimens work in treating patients with newly diagnosed FIGO stage III-IV or recurrent endometrial cancer that is stage III-IV. The study compared paclitaxel, doxorubicin, cisplatin, an active control known as the TAP regimen, to paclitaxel and carboplatin, known as the TC regimen. The trial sought to determine if doxorubicin could be omitted and carboplatin substituted for cisplatin in the front-line therapy for advanced endometrial cancer. The study found that TC is not inferior to TAP in terms of overall survival and progression-free survival and that the toxicity and quality-of-life profile favors TC over TAP.
The following have contributed to this page
